Vor Biopharma ($VOR): Putting Every Chip on Telitacicept

Executive Summary

Vor Biopharma (NASDAQ: VOR) represents a compelling and high-risk special situation investment, having undergone a dramatic transformation in mid-2025. Originally a clinical-stage company developing a novel "cell shielding" platform for hematological malignancies, Vor Bio faced severe financial distress, leading it to announce a near-total operational wind-down and a strategic review. In a stunning reversal, the company was rescued through a landmark deal that pivoted its entire focus to the autoimmune space. This involved in-licensing a late-stage, de-risked asset, telitacicept, from RemeGen and securing $175 million in new financing.

The investment thesis now rests on two core pillars: the proven leadership of the new CEO and Chairman, Dr. Jean-Paul Kress, a seasoned executive with a track record of success in similar late-stage development and commercialization scenarios; and the significant potential of telitacicept, a dual-target fusion protein that has already produced exceptionally strong Phase 3 data in China for generalized myasthenia gravis (gMG) and is approved there for other autoimmune indications.

However, the potential rewards are matched by substantial risks. The rescue financing came at the cost of extreme shareholder dilution, with over 700 million new warrants issued that could more than quintuple the share count. Despite the capital infusion, the company's cash runway is finite, and it faces a long, expensive path to its next major data catalyst—the results of the global Phase 3 trial for telitacicept, not expected until 2027. In the interim, the company must navigate a highly competitive autoimmune market, execute flawlessly on a complex global trial with a skeleton crew, and likely secure additional funding.

This report concludes that VOR is not a traditional biotech investment but a unique turnaround story. It is suitable only for investors with a very high tolerance for risk, a long-term horizon of at least three years, and a specific interest in special situations. The investment is fundamentally a bet on the ability of a proven leader to replicate prior success with a promising, late-stage asset.

Corporate Overview: A Tale of Two VORs

Understanding the investment case for Vor Biopharma requires appreciating that the company has existed in two distinct forms. The "old" VOR was a scientifically promising but financially challenged oncology pioneer. The "new" VOR is a recapitalized, single-asset company focused on autoimmunity, born from a rescue operation in June 2025.

The Original Vision: Pioneering "Shielded" Cancer Therapies

Vor Biopharma was founded on a scientifically elegant and novel concept: engineering hematopoietic stem cells (eHSCs) to make them "invisible" or "shielded" from highly potent targeted cancer therapies [1]. The company's lead program, trem-cel (tremtelectogene empogeditemcel), utilized CRISPR-Cas9 gene editing to remove the CD33 protein from healthy donor stem cells before transplantation into a patient with Acute Myeloid Leukemia (AML) [2].

The rationale was powerful: AML cells express the CD33 antigen, but so do healthy myeloid cells. This on-target, off-tumor toxicity has historically limited the effectiveness of anti-CD33 therapies [5]. By transplanting a patient with CD33-negative stem cells, the new blood and immune system would be protected, allowing for aggressive post-transplant treatment with therapies like Pfizer’s Mylotarg (gemtuzumab ozogamicin) or CD33-directed CAR-T cells to eliminate any residual cancer. This approach attracted a syndicate of premier venture capital and strategic investors, including RA Capital Management, 5AM Ventures, Johnson & Johnson Innovation, and Novartis, underscoring the initial scientific and clinical promise [4].

On the Brink of Collapse: The May 2025 Strategic Review

Despite its innovative platform, Vor Bio struggled to maintain financial footing in what it described as a "challenging fundraising environment" [10]. The company's financial situation became precarious, with its cash position falling from $137.1 million at the end of 2023 to $91.9 million by year-end 2024, and further to just $60.0 million by the end of Q1 2025 [12]. With a quarterly cash burn rate exceeding $31 million, the company was on a path to insolvency [13].

This culminated in a dramatic announcement on May 8, 2025: the Board of Directors was initiating a process to explore strategic alternatives, including a potential sale of assets, a merger, or a sale of the entire company [10]. This was not a minor course correction; it was accompanied by a drastic workforce reduction of approximately 95%, leaving a skeleton crew of only eight employees to oversee the wind-down [10]. The company's stock price had already collapsed, triggering a Nasdaq non-compliance notice on April 25, 2025, for failing to maintain a minimum bid price of $1.00 per share, putting it at risk of being delisted [16]. These events signaled a company in severe distress, on the verge of complete failure.

The Lifeline Pivot: The RemeGen Deal and Recapitalization

Just as Vor Bio appeared destined for dissolution, it announced two transformative deals on June 25, 2025, that fundamentally redefined the company and provided a critical lifeline [15].

1. The Licensing Deal: Vor Bio entered into an exclusive global license agreement (excluding Greater China) with RemeGen Co., Ltd. for telitacicept, a late-stage asset for autoimmune diseases that is already approved in China for multiple indications [15]. This single transaction pivoted the company's entire strategic focus from oncology to autoimmunity.
2. The PIPE Financing: Concurrently, Vor Bio announced a $175 million Private Investment in Public Equity (PIPE) financing. The deal was led by its largest existing stockholder, RA Capital Management, and a syndicate of other notable investors, providing the necessary capital to execute the new strategy [15].

The combination of these events was not a strategic evolution but a complete corporate rebirth. The company's near-death experience, evidenced by the 95% layoff and exploration of a sale, demonstrates that the pivot was a rescue operation orchestrated by key investors. They saw an opportunity to inject a de-risked, late-stage asset and new leadership into a publicly traded shell that was about to collapse. Therefore, an investment in VOR today is not an investment in the original cell therapy vision, but in a new entity formed in June 2025, with a new asset, new leadership, and a completely different risk-reward profile.

Table 1: VOR's Evolving Pipeline (Pre- vs. Post-Pivot)

Leadership and Strategy: The Jean-Paul Kress Era

A cornerstone of the new investment thesis for Vor Bio is the appointment of its new CEO and Chairman, Dr. Jean-Paul Kress. The decision to bring in Dr. Kress was not merely a leadership change but the central pillar of the company's recapitalization and new strategic direction.

Profile of a Turnaround Specialist: Dr. Jean-Paul Kress

Dr. Kress was appointed CEO and Chairman of the Board on June 25, 2025, replacing Robert Ang [20]. His background and experience align perfectly with Vor Bio's new mandate. Dr. Kress is a seasoned biopharma executive with a proven track record of advancing late-stage assets toward commercialization and executing strategic transactions [20].

His most relevant experience includes:

• CEO of Syntimmune: He sharpened the company's focus on late-stage clinical development in autoimmune diseases, culminating in its acquisition by Alexion [24]. This experience provides a direct blueprint for the strategy now being employed at Vor Bio with telitacicept.
• CEO of MorphoSys: He led the company through the development, approval, and commercialization of the oncology drug Monjuvi and oversaw the landmark acquisition of Constellation Pharmaceuticals, ultimately leading to MorphoSys's acquisition by Novartis in 2024 [20].
• Big Pharma Leadership: He has held senior roles at major pharmaceutical companies including Sanofi, Gilead, and Biogen, providing him with deep operational expertise in both U.S. and European markets [24].

To align his interests with shareholders, Dr. Kress was granted a substantial inducement award of over 83 million stock options with an exercise price of $0.89, vesting over a four-year period [16]. While this creates a powerful incentive for long-term value creation, it also contributes significantly to the company's massive potential share dilution.

Strategic Rationale and Execution Risk

The company's strategy has been radically simplified to an "all-in" bet on a single, high-potential asset: telitacicept [28]. This focuses all financial and operational resources on one program, which maximizes potential upside but also concentrates risk. The previous management team and organizational structure were built for early-stage research and complex cell therapy manufacturing [29]. The new organization is a lean, skeleton crew led by a commercialization expert, tasked with executing a global Phase 3 trial and navigating the complex regulatory pathways in the U.S. and Europe [10]. The primary execution risk is whether this minimalist structure can deliver on such an ambitious plan.

The hiring of Dr. Kress was the lynchpin of the entire turnaround. Investors like RA Capital were not just acquiring a molecule; they were installing a specific leader with a specific playbook to execute. An investment in VOR today is therefore, to a great extent, a direct investment in the credibility and execution capability of Jean-Paul Kress. His success or failure is inextricably linked to the company's fate.

The New Core Asset: Telitacicept and the Autoimmune Market

With the strategic pivot, Vor Bio's entire valuation now hinges on the success of a single drug, telitacicept. The asset's strong existing clinical data and large market opportunity form the foundation of the bull case.

Mechanism of Action and Clinical Validation

Telitacicept is a novel, recombinant fusion protein that offers a differentiated, dual-target mechanism of action. It simultaneously inhibits both B-Lymphocyte Stimulator (BLyS, also known as BAFF) and A Proliferation-Inducing Ligand (APRIL). These are two critical cytokines that promote the survival and maturation of B-cells, which in turn produce the pathogenic autoantibodies that drive diseases like gMG [20]. By blocking both pathways, telitacicept has the potential for more comprehensive control of autoimmune activity compared to therapies that only target a single pathway [18].

The basis for the excitement around telitacicept comes from its exceptionally strong Phase 3 clinical trial data in China (NCT05737160) for the treatment of gMG.

Table 2: Telitacicept Phase 3 China Trial (gMG) - Key Efficacy & Safety Data

This data is powerfully compelling. Furthermore, telitacicept is already approved and marketed in China for Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), which provides significant real-world evidence of its biological activity and safety profile, substantially de-risking the asset from a scientific perspective [20].

Market Opportunity and Competitive Landscape

The market for gMG is substantial and growing. The global market was estimated at approximately $1.56 billion in 2025 and is projected to reach nearly $2.95 billion by 2034 [35]. Other analyses place the market in the seven major economies (7MM) at nearly $5 billion in 2023 [36]. The broader autoimmune market, where telitacicept could potentially expand, is valued at over $100 billion annually [28].

However, this is a highly competitive space. There are at least six marketed disease-modifying therapies (DMTs) for gMG patients, and the late-stage pipeline is crowded with five other agents in development [37]. A key off-label competitor, particularly for patients with MuSK autoantibodies, is rituximab, a well-established therapy that is now available as a low-cost biosimilar, which could present a pricing and market access challenge [37]. Telitacicept's potential competitive advantage lies in its strong efficacy and its potential to work across different gMG serotypes (AChR+, MuSK+), where some competitors are more limited [32].

Path to Global Commercialization

Vor Bio has assumed responsibility for the ongoing global Phase 3 clinical trial in gMG, which is enrolling patients in the United States, Europe, and South America [20]. The single most important catalyst for the company is the top-line data from this study, which is not expected until the first half of 2027 [20]. The FDA has granted the drug Fast Track designation, which could help expedite its review upon submission [32].

While the Chinese Phase 3 data provides a tremendous de-risking event for the drug's biology, it also presents a potential trap for investors. Western regulators like the FDA and EMA will require the successful completion of the global Phase 3 study for approval; the China data alone is not sufficient. The investment thesis is therefore predicated on the assumption that the global trial will replicate the stellar Chinese results. This creates a nearly three-year "data desert," during which the company's survival and stock performance will be dictated by its financial management, competitive developments, and overall market sentiment.

The Legacy Oncology Pipeline: An Asset on the Shelf?

While Vor Bio's focus has completely shifted to autoimmunity, its original oncology assets, though now shelved, still hold potential value.

Trem-cel (eHSC Platform)

The Phase 1/2a VBP101 trial of trem-cel produced promising early data before being discontinued. All seven patients treated achieved successful primary neutrophil engraftment with a median time of just 10 days, providing strong clinical evidence that the CD33 gene is biologically dispensable for healthy hematopoiesis [7]. Critically, in the three patients who received post-transplant Mylotarg, the trem-cel graft shielded them from the expected hematologic toxicity. This data provided a powerful proof-of-concept for the entire "shielded transplant" platform [7]. The trial was discontinued as part of the May 2025 operational wind-down [11].

VCAR33 (CD33 CAR-T Program)

VCAR33, a CD33-directed CAR-T therapy, was being evaluated in the VBP301 Phase 1/2 trial for patients with relapsed/refractory AML [41]. The program had received both Fast Track and Orphan Drug designations from the FDA, highlighting its potential to address a significant unmet need [6]. This trial was also discontinued in May 2025 [11].

The highest and best use for these scientifically validated, clinically-tested oncology platforms is no longer internal development. Their value now lies in their potential as non-core assets that can be sold or out-licensed to another company. A successful partnership or sale of this legacy pipeline would represent a major positive catalyst, providing a significant, non-dilutive infusion of cash. This would extend the company's financial runway, de-risking the path to the 2027 telitacicept data readout. For investors, these shelved assets represent a valuable, hidden call option on the company's future.

Financial Analysis and Capital Structure

A critical examination of Vor Bio's financials reveals the source of its near-collapse and the immense risks that remain despite the recent recapitalization.

Historical Financial Performance and Cash Position

As a pre-revenue clinical-stage company, Vor Bio has a history of significant net losses and cash burn [13]. For the first quarter of 2025, ending March 31, the company reported:

• Revenue: $0 [13]
• Net Loss: -$32.49 million [13]
• Net Change in Cash (Cash Burn): -$31.90 million [13]
• Cash and Short-Term Investments: $60.04 million [13]

These figures illustrate an unsustainable burn rate that made the June 2025 financing an absolute necessity for survival.

The $175M PIPE and Extreme Shareholder Dilution

The $175 million PIPE financing, while a lifeline, was executed on terms that are massively dilutive to existing shareholders. The company issued 700,000,000 pre-funded warrants at a purchase price of $0.25 each [21]. These warrants have a negligible exercise price of $0.0001 per share and become exercisable upon shareholder approval [22].

Prior to this transaction, Vor Bio had approximately 125 million shares outstanding [8]. The exercise of these warrants will increase the share count by over 500%, a level of dilution that creates a substantial mathematical hurdle for future per-share value appreciation [14]. In addition, the licensing deal with RemeGen included warrants for another $80 million worth of stock, adding further to the potential dilution [20].

Table 3: VOR Key Financial Metrics & Capital Structure (Pre- vs. Post-PIPE)

Cash Runway and Future Capital Needs

While the $175 million provides a crucial runway, conducting a global Phase 3 trial is exceptionally expensive. Analysts project the current cash will only fund operations through late 2025 or into 2026 [28]. With the pivotal data readout not expected until the first half of 2027, it is a near certainty that Vor Bio will need to raise additional capital, creating an overhang of future dilution risk.

Analyst Sentiment and Valuation

Reflecting the high-risk, high-reward nature of the story, Wall Street analyst opinions are deeply fractured. Following the pivot, ratings are mixed, with a blend of "Buy" and "Hold" recommendations [45]. Price targets are in disarray, with an extremely wide range from lows of $0.25-$0.30 to highs of $3.00 or more, and averages that vary wildly depending on the source and timing of the analysis [1]. This lack of consensus underscores the profound uncertainty surrounding the company's future.

Table 4: Summary of Analyst Ratings and Price Targets (Post-June 2025 Pivot)

The financing structure effectively created a "new" company with a low-cost basis for the PIPE investors. The $0.25 per-warrant price acts as a psychological floor, representing the price at which sophisticated biotech investors were willing to recapitalize the company. For outside investors, the challenge is that the massive dilution requires a much larger increase in enterprise value to achieve the same per-share price appreciation as in the past.

Investment Thesis: A High-Risk, High-Reward Special Situation

The Bull Case: A Phoenix from the Ashes

• De-risked Lead Asset: The investment is centered on telitacicept, a drug with outstanding Phase 3 data from China and existing approvals in other indications, which significantly reduces the biological risk of failure [18].
• Proven Leadership: The company is now helmed by Dr. Jean-Paul Kress, a "turnaround specialist" whose career experience, particularly at Syntimmune, is directly analogous to the task at hand [20].
• Massive Market Opportunity: Success in gMG would unlock a multi-billion dollar market, with further potential in other large autoimmune indications [28].
• Strong Investor Syndicate: The recapitalization was led by sophisticated, long-term biotech investors like RA Capital, Forbion, and Venrock, lending significant credibility to the new strategy [21].
• Hidden Asset Value: The legacy oncology pipeline (trem-cel and VCAR33) represents a valuable, non-core asset that could be monetized to provide non-dilutive funding and extend the cash runway.
• Technical Momentum: The stock has experienced a massive price surge and a "Golden Cross" technical signal following the pivot, indicating strong renewed market interest [16].

The Bear Case: A Gamble Too Far

• Extreme Shareholder Dilution: The issuance of over 700 million new shares via warrants will massively dilute existing shareholders and create a significant mathematical headwind for share price appreciation [14].
• Financial Precariousness: Despite the PIPE, the company's cash runway is limited relative to the cost and timeline of a global Phase 3 trial. Future financing rounds and further dilution are almost certain [14].
• Long and Uncertain Timeline: The key data catalyst is not until the first half of 2027 [20]. The company must survive for nearly three years in a "data desert," making it highly vulnerable to market sentiment swings and financial pressures.
• Intense Competition: The gMG market is crowded with established players and other late-stage assets. Telitacicept will face a significant battle for market share, even if approved [37].
• Execution Risk: A skeleton crew of approximately 8 employees is now responsible for winding down old operations while simultaneously overseeing a complex, global Phase 3 trial. The risk of operational missteps is considerable [10].
• Regulatory Risk: While the China data is excellent, there is no guarantee it will be precisely replicated in the global trial to the satisfaction of the FDA and EMA.

Conclusion and Recommendation

Vor Biopharma is a company reborn. Its investment profile has been completely reshaped from that of an early-stage, science-driven oncology company to a late-stage, execution-focused autoimmune player. This is a classic "special situation" investment, where the outcome will be binary and driven by a few key factors rather than broad market trends.

The analysis concludes that VOR is suitable only for investors with a very high tolerance for risk, a long-term investment horizon (3+ years), and who are specifically seeking exposure to a high-stakes corporate turnaround. The investment is a concentrated bet on the leadership of Dr. Jean-Paul Kress and the ability of telitacicept to replicate its impressive China data on a global stage. The extreme dilution and long timeline to data cannot be overstated and make this an inappropriate holding for conservative or short-term oriented investors.

Investors considering a position should closely monitor the following key catalysts:

1. Financial Management: Quarterly reports on cash burn will be critical to assess the company's runway and the timing of potential future financings.
2. Legacy Asset Monetization: Any announcement of a sale or partnership for the trem-cel or VCAR33 oncology assets would be a significant positive catalyst, providing non-dilutive capital.
3. Clinical Trial Execution: Updates on the enrollment progress of the global Phase 3 telitacicept trial.
4. Competitive Landscape: Data readouts from competing therapies in the gMG space could impact telitacicept's perceived market potential.
5. Nasdaq Compliance: The company's plan to resolve its sub-$1.00 bid price issue, which may include a reverse stock split, will be an important near-term event.

Works cited

1. VOR - Vor Biopharma Inc. (NasdaqGS) - Share Price and News - Fintel, accessed July 7, 2025, https://fintel.io/s/us/vor
2. Platform built on Stem Cell Biology, Genome Engineering & CAR-T ..., accessed July 7, 2025, https://www.vorbio.com/platform-pipeline/our-platform/
3. Vor Biopharma and Metagenomi to Collaborate on Engineered Hematopoietic Stem-Cell Therapies, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-biopharma-and-metagenomi-collaborate-engineered/
4. Vor Biopharma Completes $42 Million Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-biopharma-completes-42-million-series-financing-round/
5. Shield the Healthy Cells, Expose the Cancer - Vor Bio, accessed July 7, 2025, https://www.vorbio.com/approach/the-concept/
6. Vor - Puretech Health, accessed July 7, 2025, https://www.puretechhealth.com/programs/details/vor
7. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT) | Blood | American Society of Hematology, accessed July 7, 2025, https://ashpublications.org/blood/article/142/Supplement%201/483/501732/Trem-Cel-a-CRISPR-Cas9-Gene-Edited-Allograft
8. Vor Biopharma Inc. Common Stock (VOR) Institutional Holdings - Nasdaq, accessed July 7, 2025, https://www.nasdaq.com/market-activity/stocks/vor/institutional-holdings
9. Vor Biopharma Expands Leadership Team with Chief Legal Officer and Vice President of People - BioSpace, accessed July 7, 2025, https://www.biospace.com/vor-biopharma-expands-leadership-team-with-chief-legal-officer-and-vice-president-of-people
10. Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-bio-announces-exploration-strategic-alternatives-maximize/
11. Vor Biopharma stock plummets on operation wind-down - Investing.com, accessed July 7, 2025, https://www.investing.com/news/stock-market-news/vor-biopharma-stock-plummets-on-operation-winddown-93CH-4033637
12. Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-bio-reports-fourth-quarter-and-full-year-2024-financial/
13. Vor Biopharma Inc (VOR) Stock Price & News - Finance - Google, accessed July 7, 2025, https://www.google.com/finance/quote/VOR:NASDAQ
14. Vor Biopharma (Nasdaq:VOR) - Stock Price, News & Analysis - Simply Wall St, accessed July 7, 2025, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma
15. Vor Biopharma Inc Ordinary Shares - Morningstar, accessed July 7, 2025, https://www.morningstar.com/stocks/xnas/vor/quote
16. Vor Biopharma Inc. Common Stock (VOR) Stock Price, Quote, News & History | Nasdaq, accessed July 7, 2025, https://www.nasdaq.com/market-activity/stocks/vor
17. Vor Biopharma faces Nasdaq delisting over low stock price By ..., accessed July 7, 2025, https://www.investing.com/news/sec-filings/vor-biopharma-faces-nasdaq-delisting-over-low-stock-price-93CH-4005391
18. Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why | Nasdaq, accessed July 7, 2025, https://www.nasdaq.com/articles/vor-bio-stock-skyrockets-250-past-week-heres-why
19. Vor Bio: Corporate Profile, accessed July 7, 2025, https://ir.vorbio.com/
20. Vor Bio Enters into Exclusive Global License Agreement with ..., accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-bio-enters-exclusive-global-license-agreement-remegen-late/
21. Vor Bio Announces $175 Million Private Placement - Stock Titan, accessed July 7, 2025, https://www.stocktitan.net/news/VOR/vor-bio-announces-175-million-private-94x0od0ys832.html
22. Vor Bio Announces $175 Million Private Placement, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-bio-announces-175-million-private-placement/
23. Vor Bio Announces $175 Million Private Placement - GlobeNewswire, accessed July 7, 2025, https://www.globenewswire.com/news-release/2025/06/25/3105467/0/en/Vor-Bio-Announces-175-Million-Private-Placement.html
24. Jean Paul Kress - Sanofi, accessed July 7, 2025, https://www.sanofi.com/en/our-company/governance/board-of-directors/jean-paul-kress
25. Vor Biopharma Inc. (VOR) Leadership & Management Team Analysis - Simply Wall St, accessed July 7, 2025, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/management
26. Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably, accessed July 7, 2025, https://www.comparably.com/companies/biogen/jean-paul-kress-m-d
27. Vor Biopharma Inc. 10-K, 10-Q, 8-K Forms - SEC-Filings - Stock Titan, accessed July 7, 2025, https://www.stocktitan.net/sec-filings/VOR/
28. Vor Bio's Bold Pivot to Autoimmune: A High-Reward Gamble on Telitacicept? - AInvest, accessed July 7, 2025, https://www.ainvest.com/news/vor-bio-bold-pivot-autoimmune-high-reward-gamble-telitacicept-2506/
29. Leadership Team - Vor Biopharma - The Org, accessed July 7, 2025, https://theorg.com/org/vor-biopharma/teams/leadership-team
30. Our People | Biotechnology Company - Vor Bio, accessed July 7, 2025, https://www.vorbio.com/about/our-people/
31. Robert Ang, President and CEO - Vor Bio, accessed July 7, 2025, https://www.vorbio.com/team/robert-ang/
32. RemeGen's Telitacicept: Revolutionizing Autoimmune Care and Unlocking Billion-Dollar Markets - AInvest, accessed July 7, 2025, https://www.ainvest.com/news/remegen-telitacicept-revolutionizing-autoimmune-care-unlocking-billion-dollar-markets-2505/
33. Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study - NeurologyLive, accessed July 7, 2025, https://www.neurologylive.com/view/investigational-telitacicept-significantly-improves-myasthenia-gravis-outcomes-phase-3-study
34. Remegen Announces Exciting Results of Telitacicept Phase 3 ..., accessed July 7, 2025, https://www.prnewswire.com/news-releases/remegen-announces-exciting-results-of-telitacicept-phase-3-clinical-trial-for-patients-with-generalized-myasthenia-gravis-302424073.html
35. www.towardshealthcare.com, accessed July 7, 2025, https://www.towardshealthcare.com/insights/myasthenia-gravis-market-sizing#:~:text=The%20global%20myasthenia%20gravis%20market,US%24%202.95%20billion%20by%202034.
36. Myasthenia Gravis Drugs Market 2034: Statistics, Revenue, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies By DelveInsight - Barchart.com, accessed July 7, 2025, https://www.barchart.com/story/news/33168049/myasthenia-gravis-drugs-market-2034-statistics-revenue-clinical-trials-ema-pdma-fda-approvals-medication-epidemiology-therapies-treatment-companies-by-delveinsight
37. AAN 2025: Remegen displays promising data for telitacicept in MG, yet faces stiff competition - Clinical Trials Arena, accessed July 7, 2025, https://www.clinicaltrialsarena.com/analyst-comment/remegen-telitacicept-mg-aan-2025/
38. www.clinicaltrialsarena.com, accessed July 7, 2025, https://www.clinicaltrialsarena.com/analyst-comment/remegen-telitacicept-mg-aan-2025/#:~:text=If%20Remegen%20wants%20to%20position,available%20as%20a%20cheap%20biosimilar.
39. Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/vor-bio-presents-positive-data-update-trem-cel-hsct2-conference/
40. Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform, accessed July 7, 2025, https://ir.vorbio.com/news-releases/news-release-details/successful-primary-engraftment-trem-cel-first-five-aml-patients/
41. VCAR33 CD33-directed CAR T Cell Therapy - Vor Bio, accessed July 7, 2025, https://www.vorbio.com/approach/programs/vcar33/
42. Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant - PAN Foundation Trial Finder, accessed July 7, 2025, https://trialfinder.panfoundation.org/en-US/trial/listing/427377
43. Vor Biopharma Earnings Dates, Reports, Calls 2015-2025 (NASDAQ - WallStreetZen, accessed July 7, 2025, https://www.wallstreetzen.com/stocks/us/nasdaq/vor/earnings
44. Vor Bio's $175M PIPE and Telitacicept Licensing: A High-Reward Gamble on Autoimmune Innovation? - AInvest, accessed July 7, 2025, https://www.ainvest.com/news/vor-bio-175m-pipe-telitacicept-licensing-high-reward-gamble-autoimmune-innovation-2506/
45. Analyst Ratings for Vor Biopharma, Inc. (VOR) [Sells] - StreetInsider, accessed July 7, 2025, https://www.streetinsider.com/rating_history.php?q=VOR&filter=sell
46. Vor Biopharma Inc. (NYSE:VOR) Receives $5.63 Average Price Target from Analysts, accessed July 7, 2025, https://www.marketbeat.com/instant-alerts/vor-biopharma-inc-nysevor-given-consensus-recommendation-of-moderate-buy-by-brokerages-2025-07-05/
47. Vor Biopharma (VOR) Stock Forecast, Price Targets and Analysts Predictions - TipRanks, accessed July 7, 2025, https://www.tipranks.com/stocks/vor/forecast
48. VOR / Vor Biopharma Inc. (NasdaqGS) - Forecast, Price Target, Estimates, Predictions, accessed July 7, 2025, https://fintel.io/sfo/us/vor
49. Vor Biopharma (VOR) Stock Forecast and Price Target 2025 - MarketBeat, accessed July 7, 2025, https://www.marketbeat.com/stocks/NYSE/VOR/forecast/
50. Vor Biopharma Inc (VOR) Stock Forecast & Price Target - Investing.com, accessed July 7, 2025, https://www.investing.com/equities/vor-biopharma-consensus-estimates
51. Generalized Myasthenia Gravis Market Forecast Report 2032 - DelveInsight, accessed July 7, 2025, https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market
52. Technical Analysis of VOR ( Vor Biopharma, Inc. ) - Kavout, accessed July 7, 2025, https://www.kavout.com/stocks/nasdaq-vor/vor-biopharma-inc/technical-analysis-5d
53. Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross | Nasdaq, accessed July 7, 2025, https://www.nasdaq.com/articles/vor-biopharma-inc-vors-technical-outlook-bright-after-key-golden-cross